Pyxis Oncology announces FDA clearance of two IND applications
The Fly

Pyxis Oncology announces FDA clearance of two IND applications

Pyxis Oncology announced that it has received clearance for its two Investigational New Drug applications from the U.S. FDA to initiate Phase 1 clinical trials. PYX-201, a novel antibody-drug conjugate product candidate, will be investigated for the potential treatment of several solid tumors, including breast, head and neck, lung, and thyroid cancer. PYX-106, an immunotherapy product candidate, will be investigated for the potential treatment of solid tumors, including bladder, cholangio-carcinoma, colorectal, and kidney cancer. Trials are expected to begin in early 2023.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on PYXS:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App